TKI Plus Checkpoint Inhibitor Without Chemotherapy Shows Promise as Initial Option in Advanced NSCLC

Co-mutations in DNA Damage-Response Pathways May Predict Effectiveness of Checkpoint Inhibitors in NSCLC

Translating Early Research to Adapt CAR T-Cell Therapy to Solid Tumors

Nivolumab Boosted Survival in Relapsed Mesothelioma

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC

LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC

Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC

Program Covers Broad Spectrum of Topics in Thoracic Oncology

Make the Most of WCLC 2023: Mobile App Launches August 31

Know Before You Go: Getting To—And Around—Singapore

Order Tickets for Special Events Today

See you in Singapore for the 2023 World Conference on Lung Cancer